| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Aprea Therapeutics, Inc. (APRE) has 10 insiders with recent SEC Form 4 filings, including 11 buys and 1 sell. APRE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 256.2K | $225.6K | - | |
| Dir | 45.8K | $40.3K | - | |
| CEO | 21.5K | $18.9K | - | |
| Dir | 10.2K | $9.0K | - | |
| Dir | 5.4K | $4.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | Hamill John P. | Srvp/ Cfo/ Prin Fin &Acct Ofcr | Buy | 5,000 | $1.17 | $5,825.00 | +22.0% | -8.9% | - | |
| Dec 10, 2025 | Duey Marc | Director | Buy | 21,459 | $1.17 | $24,999.74 | +9.1% | -8.9% | - | |
| Apr 3, 2025 | Gilad Oren | President/ CEO | Buy | 5,500 | $1.84 | $10,110.21 | +0.8% | -5.6% | -60.3% | |
| Oct 23, 2024 | Gilad Oren | President/ CEO | Buy | 500 | $3.92 | $1,957.50 | +0.2% | +3.8% | -61.0% | |
| Oct 18, 2024 | Duey Marc | Director | Sell | 6,462 | $4.58 | $29,583.04 | -2.7% | -14.9% | -64.3% | |
| Oct 16, 2024 | Duey Marc | Director | Buy | 30,000 | $4.39 | $131,700.00 | +14.3% | +3.4% | -56.0% | |
| Oct 15, 2024 | Gilad Oren | President/ CEO | Buy | 250 | $2.90 | $725.00 | - | +12.1% | -51.1% | |
| Oct 14, 2024 | Duey Marc | Director | Buy | 190 | $2.58 | $490.20 | - | +33.6% | -41.0% | |
| Oct 14, 2024 | Gilad Oren | President/ CEO | Buy | 1,150 | $2.58 | $2,971.00 | +0.2% | +33.6% | -41.0% | |
| Oct 11, 2024 | Seizinger Bernd R.49 | Director | Buy | 10,000 | $2.68 | $26,800.00 | +28.8% | +40.6% | -45.4% |